

Current Report No 16

**Patent filing application for the proprietary set of primers, diagnostic method and the reaction mixture composition to genetically diagnose Neisseria Meningitidis in LAMP technique.**

**Management Board of Genomtec S.A. (The "Issuer") informs that as of today, i.e. on July 7, 2021, a patent application has been filed for the technology developed by the Issuer. The described application concerns the proprietary set of primers, the diagnostic method and the reaction mixture composition for the genetic diagnosis of Neisseria Meningitidis in the LAMP technique. The application was filed with the Polish Patent Office, Republic of Poland.**

Neisseria Meningitidis is a species of gram-negative bacteria that causes meningitis and meningococcal sepsis. This bacterium is of great concern because infections can occur not only in the form of sporadic, endemic, hyperendemic, but also epidemic and pandemic diseases. In order to successfully treat meningococcal infection, prompt diagnosis is very important as the disease progresses very quickly.

The developed set of primers is a key element of the diagnostic method based on the LAMP technology utilized by the Issuer. Primers initiate the amplification reaction by recognizing a specific fragment of the pathogen's genome. The described patent application prevents the risk of using the same set of primers in an assay by competitors.

The Issuer's Management Board decided that filing the described patent application is a confidential information, as for an entity operating on the molecular diagnostics market it is necessary to effectively protect intellectual property and designs. Properly secured intellectual property and designs may constitute the Issuer's competitive advantage, allowing safer commercialization under condition that full protection is ensured on selected markets.

In the opinion of the Management Board, a high level of intellectual property protection will also provide the Company with a n advantageous negotiating position before signing any commercial contracts with selected partners as part of the commercialization strategy implementation.

Diagnosis of bacterial infections, including Neisseria Meningitidis, is one of the key areas of technology developed by the Issuer. For these reasons, in the opinion of the Management Board, this information meets the criteria of confidential information described in Art. 7 sec. 1 MAR.